Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab

被引：55
|
作者：
Svoboda, J
Kotloff, R
Tsai, DE
机构：
[1] Univ Penn, Ctr Canc, Div Hematol Oncol, Bone Marrow & Stem Cell Transplant Program, Philadelphia, PA 19104 USA
[2] Univ Penn, Med Ctr, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA
来源：
TRANSPLANT INTERNATIONAL | 2006年 / 19卷 / 04期
关键词：
chemotherapy; EBV < infection; monoclonal antibody; organ transplantation; PTLD < malignancies and long-term compilations; rituximab;
D O I：
10.1111/j.1432-2277.2006.00284.x
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ and bone marrow transplantations. Rituximab (Rituxan, Mabthera), a chimeric monoclonal antibody to the CD20 antigen on the surface of B-cell lymphocytes, has been used increasingly in the treatment of PTLD. Rituximab was initially approved for the treatment of low-grade non-Hodgkin lymphomas, but multiple case studies, retrospective analyses, and phase II trials demonstrate the benefit of rituximab in PTLD. This paper reviews the current data on rituximab and its promising role in the management of PTLD.
引用
收藏
页码：259 / 269
页数：11
相关论文
共 50 条
  • [1] Challenges in the management of post-transplant lymphoproliferative disorder
    Nassi, Luca
    Gaidano, Gianluca
    [J]. HEMATOLOGICAL ONCOLOGY, 2015, 33 : 96 - 99
  • [2] Post-transplant lymphoproliferative disorder treated with rituximab: case report
    Meng Hai-tao
    Li Ying
    Liu Jian-hua
    Xu Gai-xiang
    Teng Xiao-dong
    [J]. CHINESE MEDICAL JOURNAL, 2007, 120 (09) : 841 - 843
  • [3] Post-transplant lymphoproliferative disorder treated with rituximab:case report
    MENG Hai-tao LI Ying LIU Jian-hua XU Gai-xiang TENG Xiao-dong Department of Hematology (Meng HT Li Y Xu GX)Department of Stomatology (Liu JH)Department of Pathology (Teng XD)First Affiliated Hospital of Zhejiang University
    [J]. 中华医学杂志(英文版), 2007, (09) : 841 - 843
  • [4] Treatment for renal post-transplant lymphoproliferative disorder (PTLD) with rituximab
    Berthou, J.
    Nerich, V.
    Fagnoni-Legat, C.
    Bittard, H.
    Chalopin, J. M.
    Limat, S.
    [J]. PHARMACY WORLD & SCIENCE, 2008, 30 (06): : 1015 - 1015
  • [5] Post-transplant lymphoproliferative disorder treated with rituximab:case report
    MENG Haitao LI Ying LIU Jianhua XU Gaixiang TENG Xiaodong Department of Hematology Meng HT Li Y Xu GXDepartment of Stomatology Liu JHDepartment of Pathology Teng XDFirst Affiliated Hospital of Zhejiang University Hangzhou China
    [J]. Chinese Medical Journal., 2007, 120 (09) - 843
  • [6] Post-Transplant Lymphoproliferative Disorder
    Cavaliere, Kimberly
    Ganti, Anita
    Satapathy, Sanjaya K.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S1342 - S1343
  • [7] POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
    Kalinova, Lucie
    Indrakova, Jarmila
    Bachleda, Petr
    [J]. BIOMEDICAL PAPERS-OLOMOUC, 2009, 153 (04): : 251 - 257
  • [8] Post-transplant lymphoproliferative disorder
    Loren, AW
    Tsai, DE
    [J]. CLINICS IN CHEST MEDICINE, 2005, 26 (04) : 631 - +
  • [9] Reply to: Role of PET-CT in management of post-transplant lymphoproliferative disorder: Preliminary experience on the use of PET/CT in the management of pediatric post-transplant lymphoproliferative disorder
    Taj, Mary
    Guerra-Garcia, Pilar
    Hirsch, Steffen
    Levine, Daniel
    [J]. PEDIATRIC BLOOD & CANCER, 2018, 65 (02)
  • [10] Successful Treatment of Intraocular Post-Transplant Lymphoproliferative Disorder With Intravenous Rituximab
    Iu, Lawrence P.
    Yeung, Jane C.
    Loong, Florence
    Chiang, Alan K.
    [J]. PEDIATRIC BLOOD & CANCER, 2015, 62 (01) : 169 - 172
12345